Study shows ulcerative colitis patients achieve remission with probiotic composi...( trengths said Dr. Fedorak. We saw p...)

In addition to Dr. Fedorak's abstract, other studies on VSL#3 being featured at this year's DDW meeting include:

• Production of Interleukin-10 by Human Intestinal Dendritic Cells Is Upregulated by Probiotic Bacteria (ABSTRACT #102706)

• Probiotic Bacteria Induce Maturation and Modulate Cytokine Production by Human Dendritic Cells (ABSTRACT #102663)

• Probiotic Administration Induces IL-10 and Ameliorates Inflammation in Recurrent TNBS Colitis (ABSTRACT #104985)

• Probiotic Bacteria Attenuate Pro-Inflammatory Cytokine Secretion and Maintain Colonic Permeability in a Murine Model of Sepsis (ABSTRACT #T1062)

Additionally, "Origin, Characterization and Mechanisms of Action of the Probiotic VSL#3," was the subject of a presentation at a DDW Spring GRG Symposium entitled, "Host-Microbial Interactions in the GI Tract: Role of Commensal Bacteria and Probiotics."

A patented probiotic therapy, VSL#3 has been evaluated in more clinical trials of serious GI disorders than any probiotic on the market. VSL#3 is different from other probiotic therapies in that it contains numerous strains of bacteria at high concentrations (450 billion). The formulation is marketed by VSL Pharmaceuticals, Inc. and is only available to consumers through the VSL Web site, www.vslpharma.com, or by calling 1 (866) GETVSL3 (438-8753).

'"/>

Contact: Kristin Cirz
KristinC@mcspr.com
800-477-9626
MCS/VSL
19-May-2003